알레르기 면역요법 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 투여 경로별, 적응증별, 환자 그룹별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Allergy Immunotherapy Market Summary

The global allergy immunotherapy market size was valued at USD 2.1 billion in 2025 and is projected to grow from USD 2.3 billion in 2026 to USD 4.1 billion by 2033, at a CAGR of 8.9% from 2026 to 2033. Europe dominated the market, accounting for the largest revenue share of 61.6% in 2025. The market is driven by the increasing prevalence of allergic diseases, improvements in allergy diagnosis, and growing adoption of allergen immunotherapy..

Global Allergy Immunotherapy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global allergy immunotherapy market report based on product type, route of administration, indication, patient group, distribution channel, and region:

• Product Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Inhalant Allergen Immunotherapy
  • Grass Pollen Immunotherapy
  • Tree Pollen Immunotherapy
  • Weed Pollen Immunotherapy
  • House Dust Mite Immunotherapy
  • Animal Dander Immunotherapy
  • Mold (Fungal) Immunotherapy
• Venom Allergen Immunotherapy
  • Bee Venom Immunotherapy
  • Wasp Venom Immunotherapy
  • Ant Venom Immunotherapy
• Food Allergen Immunotherapy
  • Peanut Allergy Immunotherapy
  • Milk Allergy Immunotherapy
  • Egg Allergy Immunotherapy
  • Others
• Route of Administration Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
• Indication Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Allergic Rhinitis
• Allergic Asthma
• Insect Sting Allergy
• Food Allergy
• Atopic Dermatitis
• Patient Group Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Pediatric
• Adult
• Distribution Channel Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. OBJECTIVE - 1
  • 1.2.2. OBJECTIVE - 2
  • 1.2.3. OBJECTIVE - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. PURCHASED DATABASE
  • 1.4.2. GVR'S INTERNAL DATABASE
  • 1.4.3. SECONDARY SOURCES
  • 1.4.4. PRIMARY RESEARCH
• 1.5. Information or Data Analysis
  • 1.5.1. DATA ANALYSIS MODELS
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. COMMODITY FLOW ANALYSIS
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
• 3.5. Market Restraints
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Product Type Business Analysis

• 4.1. Allergy Immunotherapy Market: Product Type Movement Analysis
• 4.2. Inhalant Allergen Immunotherapy
  • 4.2.1. Inhalant Allergen Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.2.2. Grass Pollen Immunotherapy
    • 4.2.2.1. Grass Pollen Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.2.3. Tree Pollen Immunotherapy
    • 4.2.3.1. Tree Pollen Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.2.4. Weed Pollen Immunotherapy
    • 4.2.4.1. Weed Pollen Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.2.5. House Dust Mite Immunotherapy
    • 4.2.5.1. House Dust Mite Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.2.6. Animal Dander Immunotherapy
    • 4.2.6.1. Animal Dander Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.2.7. Mold (Fungal) Immunotherapy
    • 4.2.7.1. Mold (Fungal) Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
• 4.3. Venom Allergen Immunotherapy
  • 4.3.1. Venom Allergen Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.3.2. Bee Venom Immunotherapy
    • 4.3.2.1. Bee Venom Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.3.3. Wasp Venom Immunotherapy
    • 4.3.3.1. Wasp Venom Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.3.4. Ant Venom Immunotherapy
    • 4.3.4.1. Ant Venom Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
• 4.4. Food Allergen Immunotherapy
  • 4.4.1. Food Allergen Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.4.2. Peanut Allergy Immunotherapy
    • 4.4.2.1. Peanut Allergy Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.4.3. Milk Allergy Immunotherapy
    • 4.4.3.1. Milk Allergy Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.4.4. Egg Allergy Immunotherapy
    • 4.4.4.1. Egg Allergy Immunotherapy Market, 2021 - 2033 (USD Million/Billion)
  • 4.4.5. Others
    • 4.4.5.1. Others Market, 2021 - 2033 (USD Million/Billion)

Chapter 5. Route of Administration Business Analysis

• 5.1. Allergy Immunotherapy Market: Route of Administration Movement Analysis
• 5.2. Subcutaneous Immunotherapy (SCIT)
  • 5.2.1. Subcutaneous Immunotherapy (SCIT) Market, 2021 - 2033 (USD Million/Billion)
• 5.3. Sublingual Immunotherapy (SLIT)
  • 5.3.1. Sublingual Immunotherapy (SLIT) Market, 2021 - 2033 (USD Million/Billion)

Chapter 6. Indication Business Analysis

• 6.1. Allergy Immunotherapy Market: Indication Movement Analysis
• 6.2. Allergic Rhinitis
  • 6.2.1. Allergic Rhinitis Market, 2021 - 2033 (USD Million/Billion)
• 6.3. Allergic Asthma
  • 6.3.1. Allergic Asthma Market, 2021 - 2033 (USD Million/Billion)
• 6.4. Insect Sting Allergy
  • 6.4.1. Insect Sting Allergy Market, 2021 - 2033 (USD Million/Billion)
• 6.5. Food Allergy
  • 6.5.1. Food Allergy Market, 2021 - 2033 (USD Million/Billion)
• 6.6. Atopic Dermatitis
  • 6.6.1. Atopic Dermatitis Market, 2021 - 2033 (USD Million/Billion)

Chapter 7. Patient Group Business Analysis

• 7.1. Allergy Immunotherapy Market: Patient Group Movement Analysis
• 7.2. Pediatric
  • 7.2.1. Pediatric Market, 2021 - 2033 (USD Million/Billion)
• 7.3. Adult
  • 7.3.1. Adult Market, 2021 - 2033 (USD Million/Billion)

Chapter 8. Distribution Channel Business Analysis

• 8.1. Allergy Immunotherapy Market: Distribution Channel Movement Analysis
• 8.2. Hospital Pharmacies
  • 8.2.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million/Billion)
• 8.3. Retail Pharmacies
  • 8.3.1. Retail Pharmacies Market, 2021 - 2033 (USD Million/Billion)
• 8.4. Online Pharmacies
  • 8.4.1. Online Pharmacies Market, 2021 - 2033 (USD Million/Billion)

Chapter 9. Regional Business Analysis

• 9.1. Allergy Immunotherapy Market Share By Region, 2025 & 2033
• 9.2. North America
  • 9.2.1. North America Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Target Disease Prevalence
    • 9.2.2.3. Competitive Scenario
    • 9.2.2.4. Regulatory Framework
    • 9.2.2.5. Reimbursement Scenario
    • 9.2.2.6. U.S. Allergy immunotherapy market, 2021 - 2033 (USD MILLION/BILLION)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Target Disease Prevalence
    • 9.2.3.3. Competitive Scenario
    • 9.2.3.4. Regulatory Framework
    • 9.2.3.5. Reimbursement Scenario
    • 9.2.3.6. Canada Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Target Disease Prevalence
    • 9.2.4.3. Competitive Scenario
    • 9.2.4.4. Regulatory Framework
    • 9.2.4.5. Reimbursement Scenario
    • 9.2.4.6. Mexico Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
• 9.3. Europe
  • 9.3.1. Europe Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.3.2. Germany
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Target Disease Prevalence
    • 9.3.2.3. Competitive Scenario
    • 9.3.2.4. Regulatory Framework
    • 9.3.2.5. Reimbursement Scenario
    • 9.3.2.6. Germany Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.3.3. UK
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Regulatory Framework
    • 9.3.3.5. Reimbursement Scenario
    • 9.3.3.6. UK Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Competitive Scenario
    • 9.3.4.4. Regulatory Framework
    • 9.3.4.5. Reimbursement Scenario
    • 9.3.4.6. France Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Target Disease Prevalence
    • 9.3.5.3. Competitive Scenario
    • 9.3.5.4. Regulatory Framework
    • 9.3.5.5. Reimbursement Scenario
    • 9.3.5.6. Italy Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Target Disease Prevalence
    • 9.3.6.3. Competitive Scenario
    • 9.3.6.4. Regulatory Framework
    • 9.3.6.5. Reimbursement Scenario
    • 9.3.6.6. Spain Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.3.7. Denmark
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Target Disease Prevalence
    • 9.3.7.3. Competitive Scenario
    • 9.3.7.4. Regulatory Framework
    • 9.3.7.5. Reimbursement Scenario
    • 9.3.7.6. Denmark Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.3.8. Sweden
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Target Disease Prevalence
    • 9.3.8.3. Competitive Scenario
    • 9.3.8.4. Regulatory Framework
    • 9.3.8.5. Reimbursement Scenario
    • 9.3.8.6. Sweden Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Target Disease Prevalence
    • 9.3.9.3. Competitive Scenario
    • 9.3.9.4. Regulatory Framework
    • 9.3.9.5. Reimbursement Scenario
    • 9.3.9.6. Norway Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.4.2. Japan
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Competitive Scenario
    • 9.4.2.4. Regulatory Framework
    • 9.4.2.5. Reimbursement Scenario
    • 9.4.2.6. Japan Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.4.3. China
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. Regulatory Framework
    • 9.4.3.5. Reimbursement Scenario
    • 9.4.3.6. China Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. Regulatory Framework
    • 9.4.4.5. Reimbursement Scenario
    • 9.4.4.6. India Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.4.5. South Korea
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Regulatory Framework
    • 9.4.5.5. Reimbursement Scenario
    • 9.4.5.6. South Korea Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.4.6. Australia
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Regulatory Framework
    • 9.4.6.5. Reimbursement Scenario
    • 9.4.6.6. Australia Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.4.7. Thailand
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Regulatory Framework
    • 9.4.7.5. Reimbursement Scenario
    • 9.4.7.6. Thailand Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
• 9.5. Latin America
  • 9.5.1. Latin America Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Competitive Scenario
    • 9.5.2.4. Regulatory Framework
    • 9.5.2.5. Reimbursement Scenario
    • 9.5.2.6. Brazil Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. Regulatory Framework
    • 9.5.3.5. Reimbursement Scenario
    • 9.5.3.6. Argentina Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
• 9.6. MEA
  • 9.6.1. MEA Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.6.2. South Africa
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Competitive Scenario
    • 9.6.2.4. Regulatory Framework
    • 9.6.2.5. Reimbursement Scenario
    • 9.6.2.6. South Africa Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Competitive Scenario
    • 9.6.3.4. Regulatory Framework
    • 9.6.3.5. Reimbursement Scenario
    • 9.6.3.6. Saudi Arabia Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.6.4. UAE
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Competitive Scenario
    • 9.6.4.4. Regulatory Framework
    • 9.6.4.5. Reimbursement Scenario
    • 9.6.4.6. UAE Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Competitive Scenario
    • 9.6.5.4. Regulatory Framework
    • 9.6.5.5. Reimbursement Scenario
    • 9.6.5.6. Kuwait Allergy immunotherapy market, 2021 - 2033 (USD Million/Billion)

Chapter 10. Competitive Landscape

• 10.1. Participant's overview
• 10.2. Financial performance
• 10.3. Participant categorization
  • 10.3.1. Market Leaders
  • 10.3.2. Allergy immunotherapy market Share Analysis, 2025
  • 10.3.3. Company Profiles
    • 10.3.3.1. ALK-Abello
      • 10.3.3.1.1. Company Overview
      • 10.3.3.1.2. Financial Performance
      • 10.3.3.1.3. Product Benchmarking
      • 10.3.3.1.4. Strategic Initiatives
    • 10.3.3.2. Stallergenes Greer
      • 10.3.3.2.1. Company Overview
      • 10.3.3.2.2. Financial Performance
      • 10.3.3.2.3. Product Benchmarking
      • 10.3.3.2.4. Strategic Initiatives
    • 10.3.3.3. Allergy Therapeutics
      • 10.3.3.3.1. Company Overview
      • 10.3.3.3.2. Financial Performance
      • 10.3.3.3.3. Product Benchmarking
      • 10.3.3.3.4. Strategic Initiatives
    • 10.3.3.4. HAL Allergy
      • 10.3.3.4.1. Company Overview
      • 10.3.3.4.2. Financial Performance
      • 10.3.3.4.3. Product Benchmarking
      • 10.3.3.4.4. Strategic Initiatives
    • 10.3.3.5. Leti Pharma
      • 10.3.3.5.1. Company Overview
      • 10.3.3.5.2. Financial Performance
      • 10.3.3.5.3. Product Benchmarking
      • 10.3.3.5.4. Strategic Initiatives
    • 10.3.3.6. Aimmune Therapeutics
      • 10.3.3.6.1. Company Overview
      • 10.3.3.6.2. Financial Performance
      • 10.3.3.6.3. Product Benchmarking
      • 10.3.3.6.4. Strategic Initiatives
    • 10.3.3.7. DBV Technologies
      • 10.3.3.7.1. Company Overview
      • 10.3.3.7.2. Financial Performance
      • 10.3.3.7.3. Product Benchmarking
      • 10.3.3.7.4. Strategic Initiatives
    • 10.3.3.8. Torii Pharmaceutical Co., Ltd.
      • 10.3.3.8.1. Company Overview
      • 10.3.3.8.2. Financial Performance
      • 10.3.3.8.3. Product Benchmarking
      • 10.3.3.8.4. Strategic Initiatives
    • 10.3.3.9. HollisterStier Allergy (Jubilant HollisterStier LLC)
      • 10.3.3.9.1. Company Overview
      • 10.3.3.9.2. Financial Performance
      • 10.3.3.9.3. Product Benchmarking
      • 10.3.3.9.4. Strategic Initiatives
    • 10.3.3.10. Immunotek
      • 10.3.3.10.1. Company Overview
      • 10.3.3.10.2. Financial Performance
      • 10.3.3.10.3. Product Benchmarking
      • 10.3.3.10.4. Strategic Initiatives
    • 10.3.3.11. Allergopharma, Inc.
      • 10.3.3.11.1. Company Overview
      • 10.3.3.11.2. Financial Performance
      • 10.3.3.11.3. Product Benchmarking
      • 10.3.3.11.4. Strategic Initiatives
    • 10.3.3.12. Diater
      • 10.3.3.12.1. Company Overview
      • 10.3.3.12.2. Financial Performance
      • 10.3.3.12.3. Product Benchmarking
      • 10.3.3.12.4. Strategic Initiatives
    • 10.3.3.13. Roxall
      • 10.3.3.13.1. Company Overview
      • 10.3.3.13.2. Financial Performance
      • 10.3.3.13.3. Product Benchmarking
      • 10.3.3.13.4. Strategic Initiatives
    • 10.3.3.14. Probelte
      • 10.3.3.14.1. Company Overview
      • 10.3.3.14.2. Financial Performance
      • 10.3.3.14.3. Product Benchmarking
      • 10.3.3.14.4. Strategic Initiatives
    • 10.3.3.15. Lofarma
      • 10.3.3.15.1. Company Overview
      • 10.3.3.15.2. Financial Performance
      • 10.3.3.15.3. Product Benchmarking
      • 10.3.3.15.4. Strategic Initiatives
  • 10.3.4. Strategy Mapping
    • 10.3.4.1. Expansion
    • 10.3.4.2. Acquisition
    • 10.3.4.3. Collaborations
    • 10.3.4.4. Partnerships
    • 10.3.4.5. Others